Treatment in juvenile rheumatoid arthritis and new treatment options
Open Access
- 10 April 2015
- journal article
- review article
- Published by AVES YAYINCILIK A.Ş. in Turkish Archives of Pediatrics
- Vol. 50 (1), 1-10
- https://doi.org/10.5152/tpa.2015.2229
Abstract
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of the childhood with the highest risk of disability. Active disease persists in the adulthood in a significant portion of children with juvenile rheumatoid arthritis despite many developments in the diagnosis and treatment. Therefore, initiation of efficient treatment in the early period of the disease may provide faster control of the inflammation and prevention of long-term harms. In recent years, treatment options have also increased in children with juvenile idiopathic arthritis owing to biological medications. All biological medications used in children have been produced to target the etiopathogenesis leading to disease including anti-tumor necrosis factor, anti-interleukin 1 and anti-interleukin 6 drugs. In this review, scientific data about biological medications used in the treatment of rheumatoid arthritis and new treatment options will be discussed.Keywords
This publication has 43 references indexed in Scilit:
- 2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic MedicationsArthritis Care & Research, 2013
- Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic ArthritisThe New England Journal of Medicine, 2012
- Cross-cultural adaptation, reliability, and validity of the Turkish version of PedsQL 3.0 Arthritis Module: a quality-of-life measure for patients with juvenile idiopathic arthritis in TurkeyQuality of Life Research, 2012
- Safety and efficacy of tocilizumab, an anti-IL-6-receptor monoclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritisModern Rheumatology, 2011
- Juvenile idiopathic arthritisThe Lancet, 2011
- Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritisClinical Rheumatology, 2011
- Guilt by association - what is the true risk of malignancy in children treated with etanercept for JIA?Pediatric Rheumatology, 2010
- Development and validation of a composite disease activity score for juvenile idiopathic arthritisArthritis Care & Research, 2009
- Adalimumab with or without Methotrexate in Juvenile Rheumatoid ArthritisThe New England Journal of Medicine, 2008
- Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trialThe Lancet, 2008